First-in-man evaluation of intracoronary cryotherapy for vulnerable plaque stabilization
COLLET C. (1), GOGORISHVILI I. (2), CHUKHRUKIDZE A. (3), MIZUKAMI T. (4), BOUISSET F. (1), DAVIDAVICIUS G. (5), RAMUNAS U. (6)
(1) Onze Lieve Vrouwziekenhuis, Aalst BELGIUM (2) Helsicore Hospital, Tbilisi GEORGIA (3) Tbilisi Heart Center, Tbilisi GEORGIA (4) Department of Pharmacology, Showa University School of Medicine, Tokyo, Tokyo JAPAN (5) Vilnius university hospital Santaros klinikos, Vilnius City Municipality LITHUANIA (6) Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas City Municipality LITHUANIA
Company
CryoTherapeutics SA,
Rue Alfred Deponthi?re 48, 4431 Loncin, Belgium.
CEO: Dr John Yianni.
CryoTherapeutics is an early-stage European innovator developing a proprietary cryotherapy system to treat high-risk atherosclerotic plaque by delivering cryoenergy to the coronary arteries. Whilst high risk plaque that is a major cause of heart attack can now be identified using CT angiographic and intracoronary imaging, there currently is no interventional treatment available to stabilize them. Cryotherapy has been shown to be safe and effective in several medical indications. Preclinical studies of cryotherapy applied at temperatures between ?10? to ?20?C showed its potential to reduce the inflammatory process, stabilizing the vulnerable plaque with the aim to prevent its rupture.?
